WebOct 2, 2024 · CT103A is an innovative therapy co-developed by IASO BIO and Innovent Biologics, Inc. Previous studies indicated patients with relapsed/refractory multiple … WebMay 27, 2024 · CT103A was administered at 1, 3, and 6 × 106 CAR-positive T cells/kg in the dose-escalation phase, and 1 × 106 CAR-positive T cells/kg in the expansion cohort. …
S187: UPDATED PHASE 1/2 DATA OF SAFETY AND EFFICACY OF CT103A…
WebJan 4, 2024 · To evaluate the safety and efficacy of the CT103A, a self-developed BCMA-targeting CAR construct against BCMA, in patients with AQP4-IgG seropositive NMOSD, an ongoing, investigator-initiated, open-label, single-arm, phase 1 clinical trial is conducted at our center. In total, 12 patients were administered with a CAR-BCMA infusion. WebDec 22, 2024 · About CT103A. Equecabtagene autoleucel (CT103A) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure … cspp chinasoftinc.com
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory …
WebFeb 13, 2024 · About CT103A Equecabtagene autoleucel (CT103A) is a BCMA chimeric antigen receptor autologous T cell injection, a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger ... WebSep 1, 2024 · CT103A expansions were rapid and robust, with peak concentrations reached in a median of 12 days after infusion. CT103A levels remained high in most patients for at least 3 months, and in three patients CT103A persisted for >24 months. The investigators considered that the following features might contribute to the observed persistency of … Web这家CAR-T细胞企业启动科创板上市辅导,首个产品商业化在即. 近日,据中信证券官网信息显示,南京驯鹿生物技术股份有限公司(以下简称“驯鹿生物”)于2024年3月31日同中信证券签署上市辅导协议,拟科创板挂牌上市。. 官网信息显示,驯鹿生物专注于血液 ... cspp box 14